Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val (also known as 99mTc-HYNIC-I0) is a novel, fibroblast growth factor receptor 4 (FGFR4)-targeted radiopharmaceutical probe developed for the imaging of hepatocellular carcinoma (HCC). The probe consists of the octapeptide fragment Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val (I0), which is derived from the sequence of fibroblast growth factor 19 (FGF19)—an endogenous ligand of FGFR4 with high binding affinity. This peptide is conjugated to the bifunctional chelator hydrazinonicotinamide (HYNIC) and radiolabeled with technetium-99m (99mTc) using ethylenediamine-N,N'-diacetic acid (EDDA) and tricine as co-ligands. In preclinical studies, 99mTc-HYNIC-I0 demonstrated high radiochemical purity, favorable in vitro stability, and specific cellular uptake in FGFR4-expressing HepG2 cells. In vivo SPECT/CT imaging in tumor-bearing mice showed clear tumor visualization with high tumor-to-background ratios, suggesting its potential as a diagnostic imaging agent for FGFR4-positive hepatocellular carcinoma.
| Indication | Highest phase | Status |
|---|---|---|
| hepatocellular carcinoma (HCC) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: hepatocellular carcinoma (HCC)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 99mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val.
Work on 99mTc-HYNIC-Ile-Arg-Pro-Asp-Gly-Tyr-Asn-Val? Claim this page to correct or add information. Claim this page